A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions

Launched by AMPLIFIED SCIENCES INC · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a test called the PanCystPro assay, which helps doctors decide how to treat and monitor pancreatic cysts. The test looks at certain markers in the fluid taken from the cyst to determine if it is "Non-mucinous" or "Mucinous." Mucinous cysts have a higher chance of turning into cancer, while non-mucinous cysts are less likely to do so. By understanding the type of cyst, doctors can make better treatment decisions for patients.

To participate in this trial, you need to be at least 18 years old and have a pancreatic cyst that is at least 12 mm in size, as seen on imaging tests. You'll also need to provide written consent and be scheduled for an endoscopic ultrasound (EUS) where fluid will be taken from the cyst. However, if you have pancreatic cancer, are pregnant or breastfeeding, or have certain health issues that make sedation risky, you won't be eligible. This trial is not yet recruiting participants, but it aims to improve how doctors manage pancreatic cysts and potentially catch problems earlier.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years of age or older
• • Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management
• • Written informed consent.
• • The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care.
• Exclusion Criteria:
• • Patients diagnosed with pancreatic cancer.
• • Pregnant or lactating females.
• • Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness.
• • Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.